The Role of BTK Inhibitors in CLL T Cell Therapy

We see an overall response rate of 60%. The vast majority of those are complete remissions. Those patients who get complete remissions seem to have very durable disease. A nice thing about by specifics is that they don't come with the toxicity profile that we see with CAR T cell therapies where we see CRS. But I think there's a role for these drugs.